MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
Â鶹ӳ» MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphereâ„¢ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.Â
Under the agreement, the two organizations aim to advance drug development and discovery projects utilizing the MOS platform, which enables translational research on...
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
Â鶹ӳ» MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
Â鶹ӳ» MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...